News - vilanterol

Filter

Current filters:

vilanterol

Popular Filters

GlaxoSmithKline and Theravance file for EU approval of UMEC/VI for COPD

10-01-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) yesterday submitted…

AnoroBiotechnologyEuropeGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravanceUMEC/VIumeclidiniumvilanterol

US FDA accepts GSK and Theravance NDA for FF/VI; COPD drug filed in Japan

27-09-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) say that the New…

Asia-PacificfuroateGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTheravancevilanterol

GSK completes LAMA/LABA Ph III program; readies for global filings

28-08-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) say they have completed…

GlaxoSmithKlinePharmaceuticalRegulationResearchRespiratory and PulmonaryTheravanceumeclidiniumvilanterol

Positive new Ph III data from GlaxoSmithKline and Theravance on UMEC/VI

02-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) this morning announced…

GlaxoSmithKlinePharmaceuticalResearchRespiratory and PulmonaryTheravanceumeclidiniumvilanterol

Back to top